West Pharmaceutical Services (WST) has come out of Q1 2026 with investors focused on how its recent quarterly run rate and trailing figures fit together, after the company recorded Q4 2025 revenue of US$805 million, basic EPS of US$1.83 and trailing 12 month EPS of US$6.83 on revenue of about US$3.1 billion. Over the last several quarters, the company has seen revenue move from US$746.9 million in Q3 2024 to US$748.8 million in Q4 2024, then to US$766.5 million in Q2 2025, US$804.6 million in Q3 2025 and US$805 million in Q4 2025. Over the same period, quarterly EPS ranged between US$1.24 and US$1.94, setting up a results season where investors are weighing earnings growth expectations against a slightly lower trailing net margin profile.

See our full analysis for West Pharmaceutical Services.

With the recent earnings backdrop in place, the next step is to see how these numbers line up with the prevailing narratives around West Pharmaceutical Services and where the conclusions might differ.

Margins Softening With 16.1% Net Profit Level

• On a trailing 12 month basis, West Pharmaceutical Services earned US$493.7 million of net income on US$3.1b of revenue, which works out to a 16.1% net profit margin compared with 17% a year earlier.
• Consensus narrative points to higher margin HVP components and contract work in drug handling as potential supports for profitability. However, the current 16.1% margin versus 17% last year shows that, so far, margin expansion is not visible in the trailing numbers.
  • HVP components and GLP 1 related products are described as higher margin, but the trailing data captures a 0.9 percentage point margin gap rather than an uplift.
  • The expected benefits from automated HVP lines and restructuring may therefore be more of a forward story, while the latest reported margin profile still reflects cost and mix pressures.

🐂 West Pharmaceutical Services Bull Case

Revenue Trend Versus Growth Story

• Quarterly revenue moved from US$698.0 million in Q1 2025 to US$766.5 million in Q2, US$804.6 million in Q3 and US$805.0 million in Q4, while analysts are forecasting revenue growth of about 6.6% per year compared with 10.9% for the wider US market.
• Analysts' consensus view highlights GLP 1 components at roughly 7% of recent revenue and about 340 Annex 1 projects as key demand drivers. Even so, the forecast 6.6% annual revenue growth rate still trails the broader US market and shows that, even with these tailwinds, the business is not projected to grow as quickly as many other companies.

Premium P/E And DCF Gap

• West Pharmaceutical Services trades at a P/E of about 45.2x against a Global Life Sciences industry average of 35.2x and a peer average of 29.8x, while the current share price of US$309.70 sits well above a DCF fair value estimate of roughly US$190.73.
• Bears argue that a high multiple leaves little room for disappointment. The combination of a 45.2x P/E and a share price that is above the DCF fair value of US$190.73 supports that concern, especially when net margin has eased from 17% to 16.1%.
  • The P/E gap versus peers of more than 15x suggests investors are already paying up heavily relative to similar companies, even as the company’s forecast revenue growth of 6.6% annually trails the wider US market at 10.9%.
  • The spread between the US$309.70 market price and the DCF fair value indicates that, if earnings or margins do not move toward the higher levels some expect, the current valuation could be sensitive to any change in sentiment.

🐻 West Pharmaceutical Services Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for West Pharmaceutical Services on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing the mixed messages on margins, growth and valuation, it helps to see the underlying reward drivers for yourself and move quickly while sentiment is still forming. To understand what is currently drawing optimism around the stock, review the 1 key reward

See What Else Is Out There

The current picture combines a slightly softer 16.1% net margin, forecast revenue growth below the broader US market and a P/E that sits well above peer and DCF levels.

If rich valuation and slower projected growth worry you, it makes sense to quickly compare alternatives using the 58 high quality undervalued stocks to spot companies priced more conservatively.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.